vs
Apellis Pharmaceuticals, Inc.（APLS）与Industrial Logistics Properties Trust（ILPT）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是Industrial Logistics Properties Trust的1.8倍（$199.9M vs $113.9M），Industrial Logistics Properties Trust净利率更高（-1.6% vs -29.5%，领先27.9%），Industrial Logistics Properties Trust同比增速更快（3.1% vs -5.9%），Industrial Logistics Properties Trust自由现金流更多（$42.0M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 0.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Industrial Logistics Properties Trust是一家专注于工业与物流地产的房地产投资信托，主要在美国境内持有及运营配送中心、仓储设施与最后一公里配送物业，为电商、零售、制造及供应链运营企业提供仓储及物流运营相关配套服务。
APLS vs ILPT — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $113.9M |
| 净利润 | $-59.0M | $-1.8M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | -22.1% |
| 净利率 | -29.5% | -1.6% |
| 营收同比 | -5.9% | 3.1% |
| 净利润同比 | -62.2% | 92.6% |
| 每股收益（稀释后） | $-0.40 | $-0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $113.9M | ||
| Q3 25 | $458.6M | $110.9M | ||
| Q2 25 | $178.5M | $112.1M | ||
| Q1 25 | $166.8M | $111.9M | ||
| Q4 24 | $212.5M | $110.5M | ||
| Q3 24 | $196.8M | $108.9M | ||
| Q2 24 | $199.7M | $110.6M | ||
| Q1 24 | $172.3M | $112.2M |
| Q4 25 | $-59.0M | $-1.8M | ||
| Q3 25 | $215.7M | $-21.6M | ||
| Q2 25 | $-42.2M | $-21.3M | ||
| Q1 25 | $-92.2M | $-21.5M | ||
| Q4 24 | $-36.4M | $-24.1M | ||
| Q3 24 | $-57.4M | $-25.0M | ||
| Q2 24 | $-37.7M | $-23.2M | ||
| Q1 24 | $-66.4M | $-23.4M |
| Q4 25 | -25.6% | -22.1% | ||
| Q3 25 | 48.7% | -29.4% | ||
| Q2 25 | -18.6% | -30.8% | ||
| Q1 25 | -50.0% | -26.9% | ||
| Q4 24 | -12.3% | -31.1% | ||
| Q3 24 | -24.0% | -33.5% | ||
| Q2 24 | -14.7% | -32.4% | ||
| Q1 24 | -36.0% | -31.7% |
| Q4 25 | -29.5% | -1.6% | ||
| Q3 25 | 47.0% | -19.4% | ||
| Q2 25 | -23.6% | -19.0% | ||
| Q1 25 | -55.3% | -19.2% | ||
| Q4 24 | -17.1% | -21.8% | ||
| Q3 24 | -29.2% | -22.9% | ||
| Q2 24 | -18.9% | -20.9% | ||
| Q1 24 | -38.5% | -20.9% |
| Q4 25 | $-0.40 | $-0.02 | ||
| Q3 25 | $1.67 | $-0.33 | ||
| Q2 25 | $-0.33 | $-0.32 | ||
| Q1 25 | $-0.74 | $-0.33 | ||
| Q4 24 | $-0.30 | $-0.37 | ||
| Q3 24 | $-0.46 | $-0.38 | ||
| Q2 24 | $-0.30 | $-0.35 | ||
| Q1 24 | $-0.54 | $-0.36 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $94.8M |
| 总债务越低越好 | — | $4.2B |
| 股东权益账面价值 | $370.1M | $489.7M |
| 总资产 | $1.1B | $5.2B |
| 负债/权益比越低杠杆越低 | — | 8.56× |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $94.8M | ||
| Q3 25 | $479.2M | $83.2M | ||
| Q2 25 | $370.0M | $58.6M | ||
| Q1 25 | $358.4M | $108.0M | ||
| Q4 24 | $411.3M | $131.7M | ||
| Q3 24 | $396.9M | $153.9M | ||
| Q2 24 | $360.1M | $146.2M | ||
| Q1 24 | $325.9M | $128.4M |
| Q4 25 | — | $4.2B | ||
| Q3 25 | — | $4.2B | ||
| Q2 25 | — | $4.2B | ||
| Q1 25 | — | $4.3B | ||
| Q4 24 | — | $4.3B | ||
| Q3 24 | — | $4.3B | ||
| Q2 24 | — | $4.3B | ||
| Q1 24 | $93.1M | $4.3B |
| Q4 25 | $370.1M | $489.7M | ||
| Q3 25 | $401.2M | $494.1M | ||
| Q2 25 | $156.3M | $519.1M | ||
| Q1 25 | $164.2M | $539.5M | ||
| Q4 24 | $228.5M | $562.0M | ||
| Q3 24 | $237.1M | $585.9M | ||
| Q2 24 | $264.3M | $618.3M | ||
| Q1 24 | $266.7M | $643.2M |
| Q4 25 | $1.1B | $5.2B | ||
| Q3 25 | $1.1B | $5.2B | ||
| Q2 25 | $821.4M | $5.2B | ||
| Q1 25 | $807.3M | $5.4B | ||
| Q4 24 | $885.1M | $5.4B | ||
| Q3 24 | $901.9M | $5.5B | ||
| Q2 24 | $904.5M | $5.5B | ||
| Q1 24 | $831.9M | $5.5B |
| Q4 25 | — | 8.56× | ||
| Q3 25 | — | 8.49× | ||
| Q2 25 | — | 8.09× | ||
| Q1 25 | — | 7.96× | ||
| Q4 24 | — | 7.65× | ||
| Q3 24 | — | 7.35× | ||
| Q2 24 | — | 6.96× | ||
| Q1 24 | 0.35× | 6.70× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $60.7M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $42.0M |
| 自由现金流率自由现金流/营收 | -7.1% | 36.9% |
| 资本支出强度资本支出/营收 | 0.1% | 16.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $79.8M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $60.7M | ||
| Q3 25 | $108.5M | $22.7M | ||
| Q2 25 | $4.4M | $18.4M | ||
| Q1 25 | $-53.4M | $11.4M | ||
| Q4 24 | $19.4M | $2.0M | ||
| Q3 24 | $34.1M | $-3.4M | ||
| Q2 24 | $-8.3M | $10.8M | ||
| Q1 24 | $-133.0M | $8.0M |
| Q4 25 | $-14.3M | $42.0M | ||
| Q3 25 | $108.3M | $17.6M | ||
| Q2 25 | $4.4M | $15.2M | ||
| Q1 25 | $-53.4M | $5.0M | ||
| Q4 24 | $19.3M | $-3.7M | ||
| Q3 24 | — | $-5.9M | ||
| Q2 24 | $-8.4M | $9.4M | ||
| Q1 24 | $-133.3M | $5.9M |
| Q4 25 | -7.1% | 36.9% | ||
| Q3 25 | 23.6% | 15.9% | ||
| Q2 25 | 2.5% | 13.5% | ||
| Q1 25 | -32.0% | 4.5% | ||
| Q4 24 | 9.1% | -3.4% | ||
| Q3 24 | — | -5.5% | ||
| Q2 24 | -4.2% | 8.5% | ||
| Q1 24 | -77.3% | 5.2% |
| Q4 25 | 0.1% | 16.4% | ||
| Q3 25 | 0.0% | 4.6% | ||
| Q2 25 | 0.0% | 2.9% | ||
| Q1 25 | 0.0% | 5.7% | ||
| Q4 24 | 0.0% | 5.2% | ||
| Q3 24 | 0.0% | 2.3% | ||
| Q2 24 | 0.0% | 1.3% | ||
| Q1 24 | 0.2% | 1.9% |
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
ILPT
暂无分部数据
